tiprankstipranks
Advertisement
Advertisement

PRLD Stock Latest News

Prelude Therapeutics, Inc. (PRLD) Q2 Earnings Cheat Sheet
Pre-EarningsPrelude Therapeutics, Inc. (PRLD) Q2 Earnings Cheat Sheet
19d ago
PRLD
Prelude Therapeutics reports Q2 EPS (14c), consensus (19c)
PremiumThe Fly
Prelude Therapeutics reports Q2 EPS (14c), consensus (19c)
25d ago
PRLD
Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline
PremiumThe Fly
Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline
1M ago
INCY
PRLD
Prelude Therapeutics Shareholders Back Leadership and Governance
PremiumCompany Announcements
Prelude Therapeutics Shareholders Back Leadership and Governance
3M ago
8K
PRLD
Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
PremiumThe Fly
Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
4M ago
PRLD
Prelude Therapeutics Launches Phase 1 Trial and Extends Runway
PremiumCompany AnnouncementsPrelude Therapeutics Launches Phase 1 Trial and Extends Runway
4M ago
8K
PRLD
Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)
Premium
The Fly
Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)
4M ago
PRLD
Prelude Therapeutics initiated with a Buy at D. Boral Capital
Premium
The Fly
Prelude Therapeutics initiated with a Buy at D. Boral Capital
4M ago
PRLD
Prelude Therapeutics Advances First‑in‑Human PRT12396 Trial in High‑Risk Blood Cancers
PremiumCompany Announcements
Prelude Therapeutics Advances First‑in‑Human PRT12396 Trial in High‑Risk Blood Cancers
4M ago
PRLD
Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright
PremiumThe Fly
Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright
4M ago
PRLD
Prelude Therapeutics Prices Public Offering to Extend Runway
PremiumCompany Announcements
Prelude Therapeutics Prices Public Offering to Extend Runway
5M ago
8K
PRLD
Prelude Therapeutics Highlights Promising PRT13722 Preclinical Results
PremiumCompany Announcements
Prelude Therapeutics Highlights Promising PRT13722 Preclinical Results
5M ago
8K
PRLD
Prelude Therapeutics presents new preclinical data from PRT13722 study
PremiumThe FlyPrelude Therapeutics presents new preclinical data from PRT13722 study
5M ago
PRLD
Prelude Therapeutics Appoints Veteran Oncologist as New CMO
Premium
Company Announcements
Prelude Therapeutics Appoints Veteran Oncologist as New CMO
5M ago
8K
PRLD
Prelude Therapeutics announces Charles Morris as chief medical officer
Premium
The Fly
Prelude Therapeutics announces Charles Morris as chief medical officer
5M ago
PRLD
Prelude Therapeutics management to meet with Citizens
PremiumThe Fly
Prelude Therapeutics management to meet with Citizens
6M ago
PRLD
Prelude Therapeutics Establishes New ATM Equity Offering Facility
PremiumCompany Announcements
Prelude Therapeutics Establishes New ATM Equity Offering Facility
6M ago
8K
PRLD
Prelude Therapeutics price target raised to $6 from $3 at Citizens
PremiumThe Fly
Prelude Therapeutics price target raised to $6 from $3 at Citizens
6M ago
PRLD
Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program
PremiumCompany Announcements
Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program
6M ago
8K
PRLD
Prelude Therapeutics reports FY25 EPS ($1.29) vs. ($1.68) last year
PremiumThe FlyPrelude Therapeutics reports FY25 EPS ($1.29) vs. ($1.68) last year
6M ago
PRLD
Prelude Therapeutics sees cash runway into 2Q27
Premium
The Fly
Prelude Therapeutics sees cash runway into 2Q27
6M ago
PRLD
Prelude Therapeutics Wins FDA IND Clearance for PRT12396
Premium
Company Announcements
Prelude Therapeutics Wins FDA IND Clearance for PRT12396
7M ago
8K
PRLD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >